MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1479-5876
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR ; volume:10 ; number:1 ; day:6 ; month:3 ; year:2012 ; pages:1-13 ; date:12.2012
Journal of translational medicine ; 10, Heft 1 (6.3.2012), 1-13, 12.2012

Creator
Håvik, Annette Bentsen
Contributor
Brandal, Petter
Honne, Hilde
Dahlback, Hanne-Sofie Spenning
Scheie, David
Hektoen, Merete
Meling, Torstein R.
Helseth, Eirik
Heim, Sverre
Lothe, Ragnhild A.
Lind, Guro Elisabeth
SpringerLink (Online service)

DOI
10.1186/1479-5876-10-36
URN
urn:nbn:de:1111-2016041441774
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Håvik, Annette Bentsen
  • Brandal, Petter
  • Honne, Hilde
  • Dahlback, Hanne-Sofie Spenning
  • Scheie, David
  • Hektoen, Merete
  • Meling, Torstein R.
  • Helseth, Eirik
  • Heim, Sverre
  • Lothe, Ragnhild A.
  • Lind, Guro Elisabeth
  • SpringerLink (Online service)

Other Objects (12)

MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas

MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas

MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response

MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results

Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results

Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma

Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma

MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma

MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation

Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial

Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation

Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation

Related objects